Læknaneminn - 01.04.1999, Síða 44

ation explain the latitude gradient for multiple sclerosis? Ep-
idemiology 1997;8:642-5.
4. Kurtzke JF, et al. Multiple sclerosis in the Faroe Islands: trans-
mission over four epidemics. Acta Neurol Scand 1995;91:321-
5.
5. Benedikz J, Magnússon H, Guðmundsson G. Multiple scleros-
is in Iceland, with observations on the alleged epidemic in the
Faroe Islands. Ann Neurol 1994;36 Suppl 2:S175-S9.
6. Ghadirian P, et al. Nutritional factors in the aetiology of mul-
tiple sclerosis: a case-control study in Montreal, Canada. Int J
Epidemiol 1998;27:845-52.
7. Asbury, Mc Khann, Mc Donalds. Diseases of the Nervous Sy-
stem - Clinical Neurobiology. William Heinemann Medical
Books Ltd, London;1986.
8. Edland A, Nyland H, Riise T, Larsen JP. Epidemiology of mul-
tiple sclerosis in the county of Vestfold, eastern Norway: inci-
dence and prevalence calculation. Acta Neurol Scand
1996;93:104-9.
9. Casetta, et al. An epidemiological study of multiple sclerosis
in central Sardinia, Italy. Acta neurol Scand 1998;98:391-4.
10. Rothwell PM, Charlton D. High incidence and prevalence of
multiple sclerosis in south east Scotland: evidence of a genet-
ic predispotion. J Neurosurg Psyciatry 1998;64:730-5.
11. Mc Donnel GV, Hawkins SA. An epidemiologic study of mul-
tiple sclerosis in Northern Ireland. Neurology 1998;50:423-8.
12. Hopkins RS, Indian RW, Pinnow E, Conomy J. Multiple scler-
osis in Galion, Ohio: prevalence and results of a case- control
study. Neuroepidemiology 1991;10:192-9.
13. Anderson DW, et al. Revised estimate of the prevalence of
multiple sclerosis in the United States. Ann Neurol
1992;31:333-6.
14. Klein GM, Rose MS, Seland TP. A prevalence study of multi-
ple sclerosis in the Crowsnest Pass region of Southern Alberta.
CanJ Neurol Sci 1994;21:262-5.
15. Dean G, et al. Multiple sclerosis in black South Africans and
Zimbabweans. J Neurol Neurosurg Psychiatry 1994;57:1064-
9.
16. Mc Lead JG, Hammond SR, Hallpike JF. Epidemiology of
multiple sclerosis in Australia, with NSW and SA survey
results. Med J Aust 1994;160:117-22.
17. Akins, Barbara. Leisure and culture of the Australian
Aborigine. NC State University, Projects;1997.
18. Thorlacius S. Hvað er MS? 20 ára afmælisrit MS félags ís-
lands.
19. Merson RM, Rolnick Ml. Speech - language pathology and
dysphagia in multiple sclerosis. Phys Med Rehabil Clin N Am
1998;9:631-41.
20. NMSS Information Resource Center and Library. Multiple
Sclerosis. Compemdium of MS Information 1997.
21. Sigvaldadóttir E, Sveinbjörnsdóttir S. Þvag- og kynfæra-
vandamál MS sjúklinga. Meginstoð 1998;2:20-2.
22. Olafsson E. Multiple sclerosis og þunglyndi. Meginstoð
1998;2:22-3.
23. Bronnum-Hansen H, et al. Survival of patients with multiple
sclerosis in Denmark: a nationwide, long-term epidemiologic
survey. Neurology 1994;44:1901-7.
24. Wade DT. Kurtzke Multiple Sclerosis Rating Scales. Mea-
surement in neurological rehabilitation. Oxford Medical
Publications; 1992:285-9.
25. Sveinbjörnsdóttir S. Beta-interferon meðferð við MS sjúk-
dóm. Tímarit um lytjafræði 1996;2:10-14.
26. Rudick RA, et al. Cerebrospinal abnormalities in a phase III
trial of Avonex (IFN beta la) for relapsing multiple sclerosis.
The Multiple Sclerosis Collaborative Research Group. J Ne-
uroimmunol 1999;93:8-14.
27. Ozenci V, et al. Multiple sclerosis: levels of interleukin-10-
secreting blood mononuclear cells are low in untreated pati-
ents but augmented during interferon- beta lb treatment.
ScandJ Immunol 1999;49:554-61.
28. Rep MH, et al. Interferon (IFN)-beta treatment enhances
CD95 and interleukin 10 expression but reduces interferon-
gamma producing T cells in MS patients. J Neuroimmunol
1999;96:92-100.
29. Khan OA, Dhib-Jalbout SS. Neurtralizing antibodies to inter-
feron beta-la or interferon beta-lb in MS patients are cross-
reactive. Neurology 1998;51:1698-702.
30. Garrison, Susan J. Handbook of Physical Medicine and
Rehabilitation Basics. J.B. Lippincott Company;1995.
31. Jakobsson F. Um spastisk einkenni. Meginstoð 1998;2:7-11.
40
LÆKNANEMINN
1
tbl. 1999, 52. árg.